Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML

[1]  P. Thall,et al.  Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome , 2008, Leukemia.

[2]  E. Shpall,et al.  Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. , 2007, Blood.

[3]  U. Popat,et al.  Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  J. Schulte‐Mönting,et al.  Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients , 2007, Bone Marrow Transplantation.

[5]  K. Rezvani,et al.  Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. , 2006, Blood.

[6]  D. Gilliland,et al.  Drug therapy for acute myeloid leukemia. , 2005, Blood.

[7]  M. Munsell,et al.  Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[8]  S. Sohn,et al.  Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation , 2004, British journal of haematology.

[9]  L. Rybicki,et al.  Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant , 2004, Bone Marrow Transplantation.

[10]  E. Estey,et al.  Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. , 2003, Blood.

[11]  Santhosh K. P. Kumar,et al.  Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia , 2003, Leukemia.

[12]  D. Marks,et al.  Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback , 2003, Bone Marrow Transplantation.

[13]  Shaji K. Kumar,et al.  Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia , 2001, Bone Marrow Transplantation.

[14]  A. Hagemeijer,et al.  Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. , 2001, Blood.

[15]  R. Storb,et al.  Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. , 2001, Blood.

[16]  F. Frassoni,et al.  Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft‐versus‐host disease, donor type, cytomegalovirus infections and cell dose , 2001, British journal of haematology.

[17]  S. Singhal,et al.  Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. , 1998, Blood.

[18]  J. Armitage,et al.  Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Appelbaum,et al.  The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation , 1996, The oncologist.

[20]  T. D. de Witte,et al.  Clonal predominance of cytomegalovirus-specific CD8+ cytotoxic T lymphocytes in bone marrow recipients. , 1996, Bone marrow transplantation.

[21]  H. Einsele,et al.  Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. , 1993, Blood.

[22]  N. Lee,et al.  Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD , 2006, Bone Marrow Transplantation.

[23]  Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8 (cid:1) T cells , 2022 .